Tim Oldham Email & Phone Number

Melbourne, Vic, Au

AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases. AdAlta is utilising the power of the i-body technology to create a pipeline of new drugs, with an initial focus on treating fibrotic diseases.

New business creation, investment opportunity assessment, interim management and consulting. I lead firms in cell therapy, gene therapy and immunotherapy industries to design, implement and execute growth strategies and tactical operating plans with a particular focus on commercialising innovation and globalisation. I seek out and evaluate private investment opportunities and start up ventures.

Melbourne, Vic, Au

Acrux (ASX:ACR) is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred specialty and generic pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin.Fast drying, non-occlusive topical sprays or liquids provide an enhanced transdermal delivery platform with low or no skin irritation, superior cosmetic acceptability, and simple, accurate and flexible dosing.

Imunexus is transforming therapeutic antibody performance by enabling rapid, low cost and relatively low risk creation of bispecific antibodies and proteins

Respiri (formerly iSonea) is a leader in the development of mobile health devices for the management of asthma, COPD and other chronic breathing conditions. iSonea’s proprietary apps, software and devices will help people monitor the symptoms of their conditions, increase their awareness of risk of attack, adhere to their medication plans, improve outcomes and reduce healthcare expenditures.

Melbourne, Vic, Au

Cell Therapies Pty Ltd is the leading manufacturer and distributor of cellular therapies in Asia Pacific.As late stage and approved cellular therapy product numbers grow, scaling manufacturing up and out to reliably deliver a time sensitive, patient specific product with needle-to-needle control is becoming THE challenge facing the cell based therapies industry. Cell Therapies’ unique expertise is solving this challenge and we are now building on this expertise to grow our contract manufacturing and approved product distribution business into SE Asia. These markets comprise more than 650 million people and are some of the fastest growing healthcare markets in the world.Cell Therapies has more than eleven years experience with a wide range of cellular therapies for clinical trial and approved therapeutic uses. We have developed multiple processes for leading stem cell companies, that have been successfully transferred to global manufacturing networks. Cell Therapies has maintained an enviable Therapeutic Goods Administration (TGA) record at our Melbourne facilities within the Peter MacCallum Cancer Centre; and licensed our quality system to support cGMP compliance at several other facilities across Asia. The company is actively building the capabilities and client portfolio to ensure access to cell based therapies for patients across the region.

Lake Forest, Il, Us

Delivered safer and more productive intravenous drug therapy across Asia Pacific through a team of more than 400 commercial operations staff in ten countries. Achievements included establishing operations in South Korea and China; establishing (oncology) and maintaining (acute care) strategic alliances in Japan; developing innovative new product and service combinations based on customer needs in Australia (central nervous system drugs, devices and software) and China (low cost infusion management devices); and improving tendering and sales force effectiveness across the region. Total sales more than $300m, EBIT more than $75m, greater than 10% annual growth in Asia, greater than 25% in Japan and China

Led hospital injectable drug commercial operations across Europe and Middle East including preparing for integration with Hospira, overseeing business development and strategic marketing, managing six strategic alliances in India (oncology manufacturing JV, antibiotic in-licensing), Germany (contract manufacturing) and Croatia (biosimilars) and leading sales teams in 11 countries. ~EUR250m sales, 300 staff

Responsible for business development, strategic marketing, integration and alliance management. Built a centre of integration excellence. Created a pan-EU marketing function. Managed a pipeline of 20 new molecules across 35 markets including three pan-EU first to market launches and four other launches. Completed 11 transactions accessing 10 generic injectables, two biosimilars and one proprietary oncology molecule as well as Spanish subsidiary. Integrated UK chemotherapy compounding acquisition. Chair of the EGA Biosimilars Working Group that influenced in the creation of the European biosimilars market at European Commission, European Medicines Agency, WHO

Developed commercialisation strategies for step out growth ventures including biosimilars, a gene therapy for prostate cancer and proprietary drug delivery platforms

Us

Key project leadership role with pre-eminent global management consulting firm. Responsible for problem solving, client relationship and project team leadership on projects spanning a wide range of industries including healthcare, wheat, forestry, biotechnology and a range of executive management responsibilities including strategy, sales force effectiveness and direct and indirect operations productivity.

Doctor Of Philosophy (Phd), Physical Chemistry

Graduate - Company Directors Course

Graduate Diploma Of Legal Practice, Law

Bsc (Hons)/Llb (Hons), Chemistry And Intellectual Property